Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

被引：89

作者：

Dong, Jingsi ^{[1
]}

Li, Bingjie ^{[1
]}

Lin, Dan ^{[1
]}

Zhou, Qinghua ^{[1
]}

Huang, Depei ^{[2
]}

机构：

[1] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China

[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷

关键词：

NSCLC; targeted therapy; immunotherapy; EGFR; PD-L1; ALK; ROS1; DABRAFENIB PLUS TRAMETINIB; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; TYROSINE KINASE; ALK INHIBITOR; EGFR MUTATION; SINGLE-ARM; PAN-TRK; RESISTANCE; GEFITINIB;

D O I：

10.3389/fphar.2019.00230

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The essence of precision medicine is to achieve the goal of "individualized treatment" through genotyping of patients and targeted therapy. At present, the pathogenic genes of non-small cell lung cancer (NSCLC) have been studied most thoroughly and targeted therapy based on genotyping has been the most successful. This paper focuses on the precision treatment of NSCLC based on genotyping, comparing gene detection methods and summarize the latest progress of NSCLC immunotherapy.

引用

页数：10

共 80 条

[1] Epidermal growth factor receptor as a target for cancer therapy [J].

Altaha, Ramin ;

Abraham, Jame .

EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (01) :1-3

[2]

[Anonymous], INT J BIOL MARKER

[3]

[Anonymous], 2018, PRACT J MED PHARM, DOI [DOI 10.14172/J.ISSN1671-4008.2018.04.030, 10.14172/j.issn1671-4008.2018.04.030]

[4]

[Anonymous], 2014, CHIN J ONCOL

[5] Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications [J].

Ardini, Elena ;

Menichincheri, Maria ;

Banfi, Patrizia ;

Bosotti, Roberta ;

De Ponti, Cristina ;

Pulci, Romana ;

Ballinari, Dario ;

Ciomei, Marina ;

Texido, Gemma ;

Degrassi, Anna ;

Avanzi, Nilla ;

Amboldi, Nadia ;

Saccardo, Maria Beatrice ;

Casero, Daniele ;

Orsini, Paolo ;

Bandiera, Tiziano ;

Mologni, Luca ;

Anderson, David ;

Wei, Ge ;

Harris, Jason ;

Vernier, Jean-Michel ;

Li, Gang ;

Felder, Eduard ;

Donati, Daniele ;

Isacchi, Antonella ;

Pesenti, Enrico ;

Magnaghi, Paola ;

Galvani, Arturo .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (04) :628-639

[6] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer [J].

Arulananda, Surein ;

Do, Hongdo ;

Musafer, Ashan ;

Mitchell, Paul ;

Dobrovic, Alexander ;

John, Thomas .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :1728-1732

[7] MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [J].

Awad, Mark M. ;

Oxnard, Geoffrey R. ;

Jackman, David M. ;

Savukoski, Daniel O. ;

Hall, Dimity ;

Shivdasani, Priyanka ;

Heng, Jennifer C. ;

Dahlberg, Suzanne E. ;

Anne, Pasi A. J. ;

Verma, Suman ;

Christensen, James ;

Hammerman, Peter S. ;

Sholl, Lynette M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) :721-+

[8] First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib [J].

Basit, Sulman ;

Ashraf, Zaman ;

Lee, Kwangho ;

Latif, Muhammad .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 134 :348-356

[9]

Berger Stephanie, 2018, Recent Results Cancer Res, V211, P141, DOI 10.1007/978-3-319-91442-8_10

[10] Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer [J].

Blackhall, Fiona ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Soria, Jean-Charles ;

Solomon, Benjamin J. ;

Mok, Tony ;

Hirsh, Vera ;

Jaenne, Pasi A. ;

Shi, Yuankai ;

Yang, Pan-Chyr ;

De Pas, Tommaso ;

Hida, Toyoaki ;

De Castro Carpeno, Javier ;

Lanzalone, Silvana ;

Polli, Anna ;

Iyer, Shrividya ;

Reisman, Arlene ;

Wilner, Keith D. ;

Kim, Dong-Wan .

ESMO OPEN, 2017, 2 (03)

← 1 2 3 4 5 6 7 8 →